MARKHAM, ON, Dec. 22 /CNW/ - Nuvo Research Inc. (TSX:NRI) today reported
efficacy results from its preliminary analysis of the Phase III
efficacy/safety trial for Pennsaid(R), designated 'Study 112'. The results
have confirmed the effectiveness of Pennsaid(R) in the relief of the symptoms
of osteoarthritis of the knee. Pennsaid(R) is a topical non-steroidal anti-
inflammatory (NSAID) used for the treatment of osteoarthritis approved for
sale in Canada and several European countries.
